Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis

Breast Cancer

Volumn 17, Issue 4, 2010, Pages 269-275

  Nishimura, Reiki ^a   Osako, Tomofumi ^a   Okumura, Yasuhiro ^a   Hayashi, Mitsuhiro ^a   Arima, Nobuyuki ^a  

^a KUMAMOTO CITY HOSPITAL   (Japan)

Author keywords

Breast cancer; Ki 67; Neoadjuvant chemotherapy; Predictive factor

Indexed keywords

AROMATASE INHIBITOR; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; GONADORELIN DERIVATIVE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURGERY; CHEMOSENSITIVITY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PREDICTION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR VOLUME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; EPIRUBICIN; ETOPOSIDE; FEMALE; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LOGISTIC MODELS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; TAXOIDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77958105549     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0161-5     Document Type: Article

References (36)

1. B Fisher J Bryant N Wolmark E Mamounas A Brown ER Fisher DL Wickerham, et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672 2685 9704717
2. SM Scholl A Fourquet B Asselain JY Pierga JR Vilcoq JC Durand, et al. 1994 Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6 Eur J Cancer 30A 645 652 10.1016/0959-8049(94)90537-1 8080680 (Pubitemid 24164252)
3. RJ Burcombe A Makris PI Richman FM Daley S Noble M Pittam, et al. 2005 Evaluation of ER, PgR, HER2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 147 155 10.1038/sj.bjc.6602256 15611798 (Pubitemid 40188448)
4. T Petit M Wilt M Velten R Millon JF Rodier C Borel, et al. 2004 Comparative value of tumour grade, hormonal receptors, Ki-67, HER2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 205 211 10.1016/S0959-8049(03)00675-0 14728934 (Pubitemid 38077022)
5. SC Abrial F Penault-Llorca R Delva P Bougnoux B Leduc MA Mouret-Reynier, et al. 2005 High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer Breast Cancer Res Treat 94 255 263 10.1007/s10549-005-9008-8 16267618 (Pubitemid 41677630)
6. G von Minckwitz HP Sinn G Raab S Loibl JU Blohmer H Eidtmann, et al. 2008 Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast Breast Cancer Res 10 R30 10.1186/bcr1989 10.1186/bcr1989
7. KI Pritchard H Messersmith L Elavathil M Trudeau F O'Malley B Dhesy-Thind 2008 HER-2 and topoisomerase II as predictors of response to chemotherapy J Clin Oncol 26 736 744 10.1200/JCO.2007.15.4716 18258981 (Pubitemid 351264386)
8. F Andre K Broglio H Roche M Martin JR Mackey F Penault-Llorca, et al. 2008 Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with node-positive breast cancer: results from a pooled analysis J Clin Oncol 26 2636 2643 10.1200/JCO.2007.14.9146 18509176
9. J Hugh J Hanson MC Cheang TO Nielsen CM Perou C Dumontet, et al. 2009 Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 1168 1176 10.1200/JCO.2008.18.1024 19204205
10. EM Berns JA Foekens R Vossen MP Look P Devilee SC Henzen-Logmans, et al. 2000 Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer Cancer Res 60 2155 2162 10786679
11. PL Fitzgibbons DL Page D Weaver AD Thor DC Allred GM Clark, et al. 2000 Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999 Arch Pathol Lab Med 124 966 978 10888772
12. A Di Leo M Tanner C Desmedt M Paesmans F Cardoso V Durbecq, et al. 2007 p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Ann Oncol 18 997 1003 10.1093/annonc/mdm075 17369602 (Pubitemid 47050490)
13. A Di Leo L Biganzoli W Claudino S Licitra M Pestrin D Larsimont 2008 Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer 44 2791 2798 10.1016/j.ejca.2008.09.014 18993056
14. V Durbecq C Desmed M Paesmans F Cardoso A Di Leo M Mano, et al. 2004 Correlation between topoisomerase-II alpha gene amplification and protein expression in HER-2 amplified breast cancer Int J Oncol 25 1473 1479 15492841
15. J Gerdes H Lemke H Baisch HH Wacker U Schwab H Stein 1984 Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol 133 1710 1715 6206131
16. R Nishimura K Nagao H Miyayama M Matsuda K Baba Y Matsuoka, et al. 2002 An evaluation of predictive factors involved in clinical or pathological response to primary chemotherapy in advanced breast cancer Breast Cancer 9 145 152 10.1007/BF02967579 12016394
17. Giuseppe Viale Anita Giobbie-Hurder MM Regan AS Coates MG Mastropasqua P Dell'Orto, et al. 2008 Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole J Clin Oncol 26 5569 5575 10.1200/JCO.2008.17.0829 18981464
18. M Dowsett IE Smith SR Ebbs JM Dixon A Skene R A'Hern, et al. 2007 Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer J Natl Cancer Inst 99 167 170 10.1093/jnci/djk020 17228000
19. K Kai R Nishimura N Arima H Miyayama H Iwase 2006 p53 Expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study Int J Clin Oncol 11 426 433 10.1007/s10147-006-0601-6 17180510 (Pubitemid 44974395)
20. Japan Breast Cancer Society. General rules for clinical and pathological recording of breast cancer, 16th edn (in Japanese). Tokyo: Kanehara Publications; 2008.
21. K Kuroi M Toi H Tsuda M Kurosumi F Akiyama 2006 Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer Breast Cancer 13 38 48 10.2325/jbcs.13.38 16518061
22. M Kurosumi S Akashi-Tanaka F Akiyama Y Komoike H Mukai S Nakamura, et al. 2008 Histopathological criteria for assessment of therapeutic response in breast cancer (2007 version) Breast Cancer 15 5 7 10.1007/s12282-007-0016-x 18224386
23. G von Minckwitz S Kümmel P Vogel C Hanusch H Eidtmann J Hilfrich, et al. 2008 Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin- cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial J Natl Cancer Inst 100 542 551 10.1093/jnci/djn085
24. R Tashima R Nishimura 2008 Changes in biological markers, particularly hormone receptors, due to pre-operative chemotherapy (epirubicin/docetaxel) in operable breast cancer Oncol Rev 2 229 234 10.1007/s12156-008-0079-8
25. L Mauriac G MacGrogan A Avril M Durand A Floquet M Debled, et al. 1999 Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS) Ann Oncol 10 47 52 10.1023/A:1008337009350 10076721 (Pubitemid 29090591)
26. R Nishimura N Arima 2008 Is triple negative a prognostic factor in breast cancer? Breast Cancer 15 303 308 10.1007/s12282-008-0042-3 18369692
27. R Nishimura Y Okumura N Arima 2008 Trastuzumab: monotherapy versus combination therapy for treating recurrent breast cancer-time to progression and survival Breast Cancer 15 57 64 10.1007/s12282-007-0014-z 18224396
28. A Gennari MP Sormani P Pronzato M Puntoni M Colozza U Pfeffer, et al. 2008 HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials J Natl Cancer Inst 100 14 20 10.1093/jnci/djm252 18159072 (Pubitemid 351767337)
29. C Liedtke C Mazouni KR Hess F André A Tordai JA Mejia, et al. 2008 Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275 1281 10.1200/JCO.2007.14.4147 18250347
30. A Sánchez-Muñoz AM García-Tapiador E Martínez-Ortega R Dueñas-García A Jaén-Morago AL Ortega-Granados, et al. 2008 Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Clin Transl Oncol 10 646 653 10.1007/s12094-008-0265-y 18940745
31. F Peintinger AU Buzdar HM Kuerer JA Mejia C Hatzis AM Gonzalez-Angulo, et al. 2008 Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab Ann Oncol 19 2020 2025 10.1093/annonc/mdn427 18667396
32. Y Madarnas M Trudeau JA Franek D McCready KI Pritchard H Messersmith 2008 Adjuvant/neoadjuvant trastuzumab therapy in women with HER2/neu-overexpressing breast cancer: a systematic review Cancer Treat Rev 34 539 557 10.1016/j.ctrv.2008.03.013 18502589
33. A Urruticoechea IE Smith M Dowsett 2005 Proliferation marker Ki-67 in early breast cancer J Clin Oncol 23 7212 7220 10.1200/JCO.2005.07.501 16192605
34. E de Azambuja F Cardoso G de Castro M Colozza MS Mano V Durbecq 2007 Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12, 155 patients Br J Cancer 96 1504 1513 10.1038/sj.bjc. 6603756 17453008 (Pubitemid 46762956)
35. R Nishimura M Matsuda H Miyayama K Baba Y Matsuoka 2003 Proliferative activity evaluated by MIB-1 predicts the time and type of recurrence in breast cancer Breast Cancer Res Treat 82 Suppl 1 S165
36. Guarneri V, Piacentini F, Ficarra G, Frassoldati A, D'Amico R, Giovannelli S. A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. Ann Oncol. 2009. doi: 10.1093/annonc/mdn761.